Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanreotide - Ipsen

Drug Profile

Lanreotide - Ipsen

Alternative Names: Angiopeptin; BIM 23014; BIM 23014C; BM 23014; Dermopeptin; Ipstyl; ITM-014; ITM-014T; Lanreotide acetate; Lanreotide Autogel; Lanreotide PRF; Somatulina; Somatuline; Somatuline Autogel; Somatuline Depot; Somatuline LA; Somatuline LP

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwell Health; Tulane University
  • Developer Ipsen; Ipsen Biopharmaceuticals; Northwell Health; Radboud University Nijmegen Medical Centre; Teijin Pharma
  • Class Antineoplastics; Cardiovascular therapies; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Graves ophthalmopathy; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Phase III Carcinoma; Digestive system disorders; Pituitary cancer
  • Phase II Gastrointestinal motility disorders; Pancreatic cancer
  • Discontinued Atherosclerosis; Breast cancer; Coronary artery restenosis; Diabetic retinopathy; Gastrointestinal cancer; Intestinal obstruction; Leiomyoma; Lung cancer; Polycystic kidney disease; Polycystic liver disease; Portal hypertension; Prostate cancer; Rheumatic disorders

Most Recent Events

  • 31 Jul 2019 Assistance Publique - Hôpitaux de Paris and Ipsen completes a phase III trial in Polycystic kidney disease in France (NCT02127437)
  • 24 Jun 2019 The US FDA approves a new delivery device for Somatuline® Depot in USA
  • 18 Jun 2019 Ipsen completes the phase II ATLANT trial in Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Combination therapy) in Italy (SC) (NCT02698410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top